ANCA-associated vasculitis with renal involvement

Jennette JC et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthr Rheum 37:187–192

Jennette JC et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthr Rheum 65(1):1–11

Rahmattulla C et al (2016) Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann Rheum 75(9):1687–92

Maritati F et al (2016) Kidney involvement in medium- and large-vessel vasculitis. J Nephrol 29(4):495–505

Watts RA et al (2015) Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant 30(Suppl 1):14–22

Mahr A et al (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthr Rheum 51(1):92–9

O’Donnell JL et al (2007) Wegener’s granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J 37(4):242–246

Andrews M et al (1990) Systemic vasculitis in the 1980s—is there an increasing incidence of Wegener’s granulomatosis and microscopic polyarteritis? J R Coll Physicians Lond 24(4):284–288

Knight A et al (2006) Increasing incidence of Wegener’s granulomatosis in Sweden, 1975–2001. J Rheumatol 33(10):2060–2063

Radice A et al (2013) Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev 12(4):487–495

Radice A et al (2000) Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. Clin Exp Rheumatol 18(6):707–712

Taylor MV et al (2007) Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 150:42–48

Kida I et al (2011) Antineutrophil cytoplasmic antibodies against myeloperoxidase, proteinase 3, elastase, cathepsin G and lactoferrin in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21:43–50

Khanna D et al (2003) Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J Rheumatol 30:1248–1252

Kain R et al (2008) Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 14(10):1088–1096

Kain R et al (2012) High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 23(3):556–566

Shah S et al (2016) A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clin Rheumatol 35:953–960

Rowaiye OO et al (2015) The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J 8(3):343–350

Jennette JC, Falk RJ (2014) Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10(8):463–473

Xiao H et al (2015) Overview of the pathogenesis of ANCA-associated vasculitis. Kidney Dis 1(4):205–15

Popa ER et al (2002) Staphylococcus aureus and Wegener’s granulomatosis. Arthr Res 4(2):77–79

Csernok E et al (2010) Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol 22(1):43–48

Finkielman JD et al (2007) ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med 120(7):643.e9–643.14

Cornec D et al (2016) ANCA-associated vasculitis—clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 12(10):570–579

Schirmer JH et al (2016) Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German Vasculitis Referral Center. Arthr Rheumatol 68(12):2953–2963

Lyons PA et al (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367:214–223

Chung SA et al (2012) Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener’s) reveals shared susceptibility loci with rheumatoid arthritis. Arthr Rheum 64:3463–3471

Xie G et al (2013) Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthr Rheum 65:2457–2468

Hilhorst M et al (2016) HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a cohort study. Arthr Rheumatol 68:1721–1730

Jayne D (2009) The diagnosis of vasculitis. Best Pract Res Clin Rheumatol 23(3):445–453

Sinico RA et al (2013) Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev 12(4):477–482

Kallenberg CG (2014) The diagnosis and classification of microscopic polyangiitis. J Autoimmun 48–49:90–93

Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) (1998) Heptinstall’s pathology of the kidney, 5th edn. Lippincott-Raven publishers, Philadelphia, pp 625–656

Sinico RA, Meroni P (2013) The kaleidoscopic manifestations of systemic vasculitis. Autoimmun Rev 12(4):459–462

Schilder AM (2010) Wegener’s granulomatosis vasculitis and granuloma. Autoimmun Rev 9(7):483–487

Trimarchi M et al (2013) Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev 12(4):501–505

Pagnoux C (2016) Updates in ANCA-associated vasculitis. Eur J Rheumatol 3(3):122–133

Groh M et al (2015) Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545–553

Sinico RA et al (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthr Rheum 52:2926–2935

Sable-Fourtassou R et al (2005) Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med 143:632–638

Berden AE et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21(10):1628–1636

Chang DY et al (2012) Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant 27:2343–2349

Muso E et al (2013) Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol 17(5):659–662

Moroni G et al (2015) Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopathological classification schema and review of the literature. Clin Exp Rheumatol 33(2 Suppl 89):S56–S63

Tanna A et al (2015) Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant 30:1185–1192

Hilhorst M et al (2013) Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 28:373–379

Quintana LF et al (2014) ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 29:1764–1769

Ford SL et al (2014) Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis 63:227–235

Bjorneklett R et al (2016) Prognostic value of histologic classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 11(12):2159–2167

Diaz-Crespo F et al (2016) The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. Hum Pathol 52:119–127

Yates M et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594

Novack SN, Pearson CM (1971) Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 284:938–942

De Groot K et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680

Guillevin L et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthr Rheum 40:2187–2198

Harper L et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960

Cohen P et al (2007) Churg–Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthr Rheum 57:686–693

Jones RB et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220

Stone JH et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232

Mohammad AJ et al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 75:396–401

Jayne DR et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. European Vasculitis Study Group. J Am Soc Nephrol 18(7):2180–2188

Walsh M et al (2013) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14:73

Jayne D et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44

Guillevin L et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780

Pagnoux C et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803

Hiemstra TF et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304:2381–2388

Flossmann O et al (2010) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494

Westman K, Flossmann O, Gregorini G (2015) The long-term outcomes of systemic vasculitis. Nephrol Dial Transplant 30(Suppl 1):60–66

Chang DY et al (2012) Association of HLA genes with clinical outcomes of ANCA-associated vasculitis. Clin J Am Soc Nephrol 7:1293–1299

Slot MC et al (2003) Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 63:670–677

Hogan SL et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631

Moroni G, Ponticelli C (2014) Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev 13:723–729